AR069802A1 - Compuestos de carbamoilo como inhibidores de dgat1 190 - Google Patents
Compuestos de carbamoilo como inhibidores de dgat1 190Info
- Publication number
- AR069802A1 AR069802A1 ARP080105523A ARP080105523A AR069802A1 AR 069802 A1 AR069802 A1 AR 069802A1 AR P080105523 A ARP080105523 A AR P080105523A AR P080105523 A ARP080105523 A AR P080105523A AR 069802 A1 AR069802 A1 AR 069802A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- alkyl
- alkoxy
- carbon atom
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se describen compuestos inhibidores de DGAT-1 de la formula (1), sales y prodrogas farmacéuticamente aceptables de los mismos, conjuntamente con composiciones farmacéuticas, y su uso en el tratamiento, por ejemplo, de la obesidad. Reivindicacion 1: Un compuesto de la formula (1), o una sal, o prodroga farmacéuticamente aceptable del mismo, en donde El anillo A es 2,6-pirazindiilo, 3,5-piridindiilo o 2,6-piridindiilo, cada uno opcionalmente sustituido sobre un átomo de carbono disponible con uno o dos sustituyentes independientemente seleccionados de alquilo C1-3 lineal, alquenilo C2-3; alquinilo C2-3; alcoxi C1-2, metoximetilo, amino y ciano; X es =O o =S; el anillo B es 1,4-fenileno o el anillo B es un anillo di-unido (excluyendo las uniones a través de los mismos átomos o de átomos adyacentes) seleccionado de piridindiilo, furandiilo, tiofendiilo, pirroldiilo, oxazoldiilo, tiazoldiilo, imidazoldiilo, isoxazoldiilo, isotiazoldiilo y pirazoldiilo; cada uno opcionalmente sustituido sobre un átomo de carbono disponible con uno o dos sustituyentes independientemente seleccionados de halo, amino, ciano, alquilo C1-4, alquenilo C2-3; alquinilo C2-3; alcoxi C1-4 y alcoxi C1-4-alquilo C1-4; Y1 es un enlace directo entre el anillo B y el anillo C o Y1 es -O-, -S- o -NRa- en donde Ra es hidrogeno o alquilo C1-4; Y2 es -(CH2)r en donde r es 2 o 3, e Y2 está unido en el mismo átomo de carbono que Y1 en el anillo C e Y2 está unido a un átomo de carbono adyacente a Y1 en el anillo B; n es 0 o n es 1 cuando Y1 es un enlace directo entre el anillo B y el anillo C y cuando el anillo B es 1,4-fenileno y el anillo C es cicloalcano C4-6, de modo que se forme un sistema de anillos espiro de 5 o 6 miembros y el anillo C se encuentre tri-unido; el anillo C es un anillo o sistema de anillos di-unido (excluyendo las uniones a través de los mismos átomos o de átomos adyacentes) seleccionado de cicloalcano C4-6, bicicloalcano C7-10 y tricicloalcano C8-12 cada uno opcionalmente sustituido sobre un átomo de carbono disponible, incluyendo el átomo de carbono del anillo que porta al grupo que contiene a Z, con un sustituyente seleccionado de hidroxi, alquilo C1-4, alcoxi C1-4 y alcoxi C1-4-alquilo C1-4; o el anillo C es un anillo di-unido (excluyendo las uniones a través de los mismos átomos o de átomos adyacentes) seleccionado de fenileno, piridindiilo, piperidindiilo N-unido a Y1, piperazindiilo, furandiilo, tiofendiilo, pirroldiilo, oxazoldiilo, tiazoldiilo, imidazoldiilo, isoxazoldiilo, isotiazoldiilo, pirazoldiilo y azabiciclo[3.1.0]hexandiilo; cada uno opcionalmente sustituido sobre un átomo de carbono disponible con hasta cuatro sustituyentes independientemente seleccionados de fluor, cloro, bromo, ciano, alquilo C1-4, alcoxi C1-4 y alcoxi C1-4-alquilo C1-4; L es un enlace directo al anillo C, -O-, -S- o -NH-; p es 0, 1 o 2 y cuando p es 1 RA1 y RA2 son cada uno independientemente hidrogeno o alquilo C1-4 o RA1 y RA2 están unidos conjuntamente para formar un anillo espiroalquilo C3-6; Z es carboxi o un mímico o bioisostero del mismo, hidroxi o -CONRbRc en donde Rb y Rc están independientemente seleccionados de hidrogeno y alquilo C1-4, cuyo grupo alquilo C1-4 puede estar opcionalmente sustituido con carboxi o un mímico o bioisostero del mismo; y en donde cualquier átomo de carbono en un grupo que contiene alquilo C1-3 lineal, alcoxi C1-2, alquilo C1-4 o alcoxi C1-4 definido precedentemente puede estar opcionalmente sustituido con hasta 3 átomos de fluor; con la condicion de que el compuesto ácido (4-(4-(6-carbamoil-piridin-2-il)fenil)ciclohexil)acético se encuentre excluido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1539707P | 2007-12-20 | 2007-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069802A1 true AR069802A1 (es) | 2010-02-17 |
Family
ID=40427160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105523A AR069802A1 (es) | 2007-12-20 | 2008-12-18 | Compuestos de carbamoilo como inhibidores de dgat1 190 |
Country Status (23)
Country | Link |
---|---|
US (2) | US7994179B2 (es) |
EP (1) | EP2234978B1 (es) |
JP (1) | JP5662803B2 (es) |
KR (1) | KR20100099738A (es) |
CN (1) | CN101932562B (es) |
AR (1) | AR069802A1 (es) |
AU (1) | AU2008339570B2 (es) |
BR (1) | BRPI0821274A2 (es) |
CA (1) | CA2707660A1 (es) |
CL (1) | CL2008003847A1 (es) |
CO (1) | CO6290685A2 (es) |
CR (1) | CR11518A (es) |
DO (1) | DOP2010000192A (es) |
EA (1) | EA201001015A1 (es) |
EC (1) | ECSP10010274A (es) |
ES (1) | ES2535083T3 (es) |
IL (1) | IL206045A0 (es) |
NI (1) | NI201000108A (es) |
NZ (1) | NZ586104A (es) |
PE (1) | PE20091682A1 (es) |
TW (1) | TW200932235A (es) |
WO (1) | WO2009081195A1 (es) |
ZA (1) | ZA201003979B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005315430B2 (en) * | 2004-12-14 | 2010-05-27 | Astrazeneca Ab | Oxadiazole derivatives as DGAT inhibitors |
WO2007071966A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors |
SI2402317T1 (sl) | 2006-03-31 | 2013-10-30 | Novartis Ag | DGAT inhibitor |
AU2007266796B2 (en) | 2006-05-30 | 2011-02-10 | Astrazeneca Ab | Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
KR20090010092A (ko) * | 2006-05-30 | 2009-01-28 | 아스트라제네카 아베 | Dgat1 억제제로서의 1,3,4-옥사디아졸 유도체 |
ES2359653T3 (es) * | 2006-06-08 | 2011-05-25 | Astrazeneca Ab | Bencimidazoles y su uso para el tratamiento de la diabetes. |
JP5203360B2 (ja) | 2006-06-23 | 2013-06-05 | アボット・ラボラトリーズ | ヒスタミンh3受容体調節剤としてのシクロプロピルアミン誘導体 |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
BRPI0815490A2 (pt) * | 2007-08-17 | 2017-03-21 | Astrazeneca Ab | composto, composição faramcêutica, método para tratar diabetes mellitus e/ou obesidade em um animal de sangue quente, e, processo para preparar um composto |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
AU2009329345A1 (en) * | 2008-12-19 | 2011-06-30 | Astrazeneca Ab | 1,3,4-oxadiazole derivatives and their uses to treat diabetes |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
KR20120037939A (ko) | 2009-06-19 | 2012-04-20 | 아스트라제네카 아베 | Dgat1의 억제제로서 피라진 카르복사미드 |
WO2011054530A1 (en) * | 2009-11-05 | 2011-05-12 | Fibrostatin, S.L. | Gpbp inhibition using q2 peptidomimetics |
TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基-雜芳基衍生物及其使用方法 |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
WO2012064569A1 (en) * | 2010-11-08 | 2012-05-18 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
US9045389B2 (en) * | 2011-05-23 | 2015-06-02 | Janssen Pharmaceutica Nv | Biphenyl derivatives useful as glucagon receptor antagonists |
TW201307287A (zh) * | 2011-05-30 | 2013-02-16 | Daiichi Sankyo Co Ltd | 環烷基氧基聯芳基型化合物 |
WO2013068328A1 (en) * | 2011-11-07 | 2013-05-16 | Intervet International B.V. | Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors |
WO2013074387A1 (en) * | 2011-11-14 | 2013-05-23 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
CN104245696A (zh) * | 2012-02-07 | 2014-12-24 | 凯诺斯医药公司 | 作为1型二酰基甘油o-酰基转移酶的抑制剂的化合物 |
AP3592A (en) * | 2012-04-27 | 2016-02-15 | Novartis Ag | Cyclic bridgehead ether dgat1 inhibitors. |
US8987461B2 (en) | 2012-12-06 | 2015-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
US8962660B2 (en) * | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
KR102225715B1 (ko) * | 2013-07-09 | 2021-03-09 | 토소가부시키가이샤 | 아다만틸기를 가진 환상 아진 화합물, 제조 방법, 및 상기 화합물을 구성 성분으로서 함유하는 유기 전계발광소자 |
CA2931313C (en) | 2013-11-21 | 2022-04-05 | Marquette University | Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform |
ES2881706T3 (es) * | 2014-03-12 | 2021-11-30 | Astrazeneca Ab | Método de tratamiento de las afecciones de la piel |
CA3101064A1 (en) * | 2018-06-21 | 2019-12-26 | Dermavant Sciences GmbH | Topical formulations of dgat1 inhibitors and their methods of use |
EP3590927A1 (en) | 2018-07-05 | 2020-01-08 | Bayer Animal Health GmbH | Novel compounds for controlling arthropods |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
WO2020214693A1 (en) * | 2019-04-17 | 2020-10-22 | Ixchel Pharma, Llc | Prodrugs of monomethyl fumarate |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3245989A (en) | 1962-12-15 | 1966-04-12 | Acraf | 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles |
US4983731A (en) | 1989-03-17 | 1991-01-08 | Nebraska Department Of Economic Development | Separation and purification of sugar esters |
US5491172A (en) | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
IL109431A (en) | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
US20030167483A1 (en) | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
AU2856499A (en) | 1999-03-25 | 2000-10-16 | Kitasato Institute, The | Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same |
TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
CA2369967A1 (en) | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
JP2002284741A (ja) | 2001-03-23 | 2002-10-03 | Kitasato Inst:The | ローズリピン誘導体 |
RS50889B (sr) | 2001-08-31 | 2010-08-31 | Sanofi-Aventis Deutschland Gmbh. | Derivati diaril-cikloalkila, postupak za njihovu proizvodnju i njihova primena u svojstvu ppar aktivatora |
DE10223273A1 (de) | 2002-05-24 | 2003-12-04 | Aventis Pharma Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP1448556A1 (en) * | 2001-11-01 | 2004-08-25 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
FR2840301B1 (fr) | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4アンタゴニストおよびその医薬用途 |
JP2006502247A (ja) | 2002-07-12 | 2006-01-19 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 複素環で置換されたベンゾイル尿素、その製造方法および医薬としてのその使用 |
JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Dgat阻害剤 |
JP2005536554A (ja) | 2002-08-23 | 2005-12-02 | ユニバーシティ オブ コネチカット | 新規なビフェニル及びビフェニル様カンナビノイド |
US6875784B2 (en) | 2002-10-09 | 2005-04-05 | Pharmacia & Upjohn Company | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives |
AU2003287178A1 (en) | 2002-10-10 | 2004-05-04 | Smithkline Beecham Corporation | Chemical compounds |
MXPA05005425A (es) | 2002-11-22 | 2005-11-23 | Japan Tobacco Inc | Heterociclos que contienen nitrogeno, biciclicos, fusionados. |
CN102267924A (zh) | 2003-01-08 | 2011-12-07 | 诺华疫苗和诊断公司 | 抗菌剂 |
JP4847314B2 (ja) | 2003-04-07 | 2011-12-28 | コーティカル・ピーティーワイ・リミテッド | 炎症性疾患を治療するための新規な方法 |
AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
BRPI0410348A (pt) | 2003-05-14 | 2006-05-30 | Torreypines Therapeutics Inc | compostos e usos dos mesmos na modulação de amilóide-beta |
JP2007501801A (ja) | 2003-08-07 | 2007-02-01 | 日本たばこ産業株式会社 | ピロロ[1,2−b]ピリダジン誘導体 |
EP1661889A4 (en) | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
US20050143464A1 (en) | 2003-09-22 | 2005-06-30 | Use-Techno Corporation | Insulin secretion potentiator |
JP4956191B2 (ja) | 2003-10-17 | 2012-06-20 | インサイト コーポレーション | マトリックスメタロプロテイナーゼの阻害剤としての置換環状ヒドロキサメート |
GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
US20050101660A1 (en) | 2003-11-11 | 2005-05-12 | The Skinny Drink Company | Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease |
JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
AU2005209115A1 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
US20070249620A1 (en) | 2004-07-02 | 2007-10-25 | Hitoshi Kurata | Urea Derivative |
WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
EP1805156B1 (en) | 2004-10-15 | 2010-12-22 | Bayer HealthCare LLC | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
WO2006054370A1 (en) | 2004-11-16 | 2006-05-26 | Use-Techno Corporation | Gluconeogenesis inhibiting agent |
AU2005315430B2 (en) | 2004-12-14 | 2010-05-27 | Astrazeneca Ab | Oxadiazole derivatives as DGAT inhibitors |
EP1845081A4 (en) | 2005-02-01 | 2009-03-25 | Takeda Pharmaceutical | amide |
AU2006210056A1 (en) | 2005-02-07 | 2006-08-10 | F. Hoffmann-La Roche Ag | Inhibitors of diacylglycerol acyltransferase (DGAT) |
US20090215780A1 (en) | 2005-04-19 | 2009-08-27 | Bayer Pharmaceuticals Corporation | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity |
JP2008540485A (ja) | 2005-05-10 | 2008-11-20 | エフ.ホフマン−ラ ロシュ アーゲー | ジアシルグリセロールアシルトランスフェラーゼ阻害剤 |
CA2610188A1 (en) | 2005-06-11 | 2006-12-21 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
EP1912634A4 (en) | 2005-07-29 | 2010-06-09 | Bayer Healthcare Llc | PREPARATION AND USE OF BIPHENYL AMINOACIDAL DERIVATIVES TO TREAT OBESITY |
JP2007131584A (ja) | 2005-11-11 | 2007-05-31 | Sankyo Co Ltd | 新規ベンゾオキサゾール誘導体 |
WO2007060140A2 (en) | 2005-11-28 | 2007-05-31 | F. Hoffmann-La Roche Ag | Inhibitors of diacyglycerol acyltransferase (dgat) |
JP2007191471A (ja) | 2005-12-21 | 2007-08-02 | Sankyo Co Ltd | ウレア誘導体を含有する医薬 |
WO2007071966A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors |
WO2007074753A1 (ja) | 2005-12-27 | 2007-07-05 | Daiichi Sankyo Company, Limited | 置換されたウレア誘導体を含有する医薬 |
SI2402317T1 (sl) | 2006-03-31 | 2013-10-30 | Novartis Ag | DGAT inhibitor |
EP2016047B1 (en) | 2006-04-21 | 2013-08-28 | Eli Lilly And Company | Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1 |
WO2007137103A2 (en) | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2007137107A2 (en) | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
AU2007266796B2 (en) | 2006-05-30 | 2011-02-10 | Astrazeneca Ab | Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
KR20090010092A (ko) | 2006-05-30 | 2009-01-28 | 아스트라제네카 아베 | Dgat1 억제제로서의 1,3,4-옥사디아졸 유도체 |
JP2009539816A (ja) | 2006-06-06 | 2009-11-19 | アストラゼネカ アクチボラグ | 化学化合物 |
ES2359653T3 (es) | 2006-06-08 | 2011-05-25 | Astrazeneca Ab | Bencimidazoles y su uso para el tratamiento de la diabetes. |
GB0611507D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
GB0611506D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
GB0611552D0 (en) | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
WO2008011130A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
EP2044055A4 (en) | 2006-07-21 | 2011-03-23 | Takeda Pharmaceutical | amide compounds |
US7569590B2 (en) | 2006-09-19 | 2009-08-04 | Bristol-Myers Squibb Company | Use of thianecarboxamides as dgat inhibitors |
KR100811100B1 (ko) | 2006-09-27 | 2008-03-06 | 한국생명공학연구원 | 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물 |
KR100795462B1 (ko) | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
EP2084146B1 (en) | 2006-10-04 | 2013-08-21 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
BRPI0717845A2 (pt) | 2006-10-04 | 2015-06-16 | Hoffmann La Roche | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos |
AR063311A1 (es) | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
JP2010510177A (ja) | 2006-11-17 | 2010-04-02 | クイーンズ ユニバーシティ アット キングストン | タンパク質フォールディング障害を治療するための化合物および方法 |
JP2010511058A (ja) | 2006-11-29 | 2010-04-08 | アボット・ラボラトリーズ | ジアシルグリセロールo−アシルトランスフェラーゼ1型酵素の阻害薬 |
MX2009006171A (es) | 2006-12-11 | 2009-06-19 | Novartis Ag | Metodo para la prevencion o el tratamiento de isquemia de miocardio. |
EP2120911A1 (en) | 2007-02-15 | 2009-11-25 | Prosidion Limited | Amide and urea derivatives for the treatment of metabolic diseases |
GB0707662D0 (en) | 2007-04-20 | 2007-05-30 | Astrazeneca Ab | Chemical compounds |
MX2009011754A (es) | 2007-04-30 | 2009-12-01 | Abbott Lab | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. |
US8058299B2 (en) | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
JP2010132590A (ja) | 2008-12-03 | 2010-06-17 | Astellas Pharma Inc | オキサジアゾール化合物 |
AU2009329345A1 (en) | 2008-12-19 | 2011-06-30 | Astrazeneca Ab | 1,3,4-oxadiazole derivatives and their uses to treat diabetes |
-
2008
- 2008-12-18 AU AU2008339570A patent/AU2008339570B2/en not_active Expired - Fee Related
- 2008-12-18 CN CN2008801259853A patent/CN101932562B/zh not_active Expired - Fee Related
- 2008-12-18 BR BRPI0821274A patent/BRPI0821274A2/pt not_active IP Right Cessation
- 2008-12-18 NZ NZ586104A patent/NZ586104A/en not_active IP Right Cessation
- 2008-12-18 WO PCT/GB2008/051199 patent/WO2009081195A1/en active Application Filing
- 2008-12-18 EP EP08865783.8A patent/EP2234978B1/en active Active
- 2008-12-18 AR ARP080105523A patent/AR069802A1/es not_active Application Discontinuation
- 2008-12-18 TW TW097149460A patent/TW200932235A/zh unknown
- 2008-12-18 KR KR1020107016252A patent/KR20100099738A/ko not_active Application Discontinuation
- 2008-12-18 CA CA2707660A patent/CA2707660A1/en not_active Abandoned
- 2008-12-18 ES ES08865783.8T patent/ES2535083T3/es active Active
- 2008-12-18 EA EA201001015A patent/EA201001015A1/ru unknown
- 2008-12-18 PE PE2008002123A patent/PE20091682A1/es not_active Application Discontinuation
- 2008-12-18 JP JP2010538918A patent/JP5662803B2/ja not_active Expired - Fee Related
- 2008-12-19 CL CL2008003847A patent/CL2008003847A1/es unknown
- 2008-12-19 US US12/339,349 patent/US7994179B2/en not_active Expired - Fee Related
-
2010
- 2010-05-27 IL IL206045A patent/IL206045A0/en unknown
- 2010-06-03 ZA ZA2010/03979A patent/ZA201003979B/en unknown
- 2010-06-18 NI NI201000108A patent/NI201000108A/es unknown
- 2010-06-18 EC EC2010010274A patent/ECSP10010274A/es unknown
- 2010-06-18 DO DO2010000192A patent/DOP2010000192A/es unknown
- 2010-06-18 CR CR11518A patent/CR11518A/es not_active Application Discontinuation
- 2010-06-21 CO CO10074457A patent/CO6290685A2/es not_active Application Discontinuation
-
2011
- 2011-05-05 US US13/101,926 patent/US20120108602A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DOP2010000192A (es) | 2010-07-15 |
AU2008339570A1 (en) | 2009-07-02 |
CN101932562A (zh) | 2010-12-29 |
CA2707660A1 (en) | 2009-07-02 |
EP2234978A1 (en) | 2010-10-06 |
BRPI0821274A2 (pt) | 2017-06-13 |
US20090298853A1 (en) | 2009-12-03 |
ECSP10010274A (es) | 2010-07-30 |
EA201001015A1 (ru) | 2011-02-28 |
US7994179B2 (en) | 2011-08-09 |
CN101932562B (zh) | 2013-06-12 |
AU2008339570B2 (en) | 2012-04-12 |
NI201000108A (es) | 2012-05-14 |
CL2008003847A1 (es) | 2009-11-27 |
JP2011507823A (ja) | 2011-03-10 |
NZ586104A (en) | 2012-02-24 |
JP5662803B2 (ja) | 2015-02-04 |
CR11518A (es) | 2010-07-15 |
CO6290685A2 (es) | 2011-06-20 |
ZA201003979B (en) | 2011-11-30 |
EP2234978B1 (en) | 2015-02-25 |
ES2535083T3 (es) | 2015-05-05 |
PE20091682A1 (es) | 2009-12-04 |
US20120108602A1 (en) | 2012-05-03 |
IL206045A0 (en) | 2010-11-30 |
TW200932235A (en) | 2009-08-01 |
KR20100099738A (ko) | 2010-09-13 |
WO2009081195A1 (en) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069802A1 (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
HRP20130900T1 (hr) | Derivat (aza)indola i njegova uporaba u medicinske svrhe | |
AR072779A1 (es) | Inhibidores macrociclicos de la replicacion del virus de la hepatitis c | |
CO6220931A2 (es) | Inhibidores de serina proteasas para el tratamiento de infecciones de vhc | |
AR066882A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
AR066043A1 (es) | Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1) | |
AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
ECSP055886A (es) | Derivados de isoindolina | |
AR057072A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
RS53679B1 (en) | FURAZANOBENZIMIDAZOLES AS PROGRAMS FOR THE TREATMENT OF NEOPLASTIC OR AUTOIMMUNE DISEASES | |
AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
AR070801A1 (es) | Derivados pirimidin -piridina | |
AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
AR069436A1 (es) | Compuestos de piridina | |
AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. | |
RS53389B (en) | PHARMACEUTICAL UNITS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |